Marval Biosciences

Marval Biosciences is a preclinical-stage biotechnology company developing a new class of contrast agents for X-ray and Computed Tomography (CT) imaging. The company's proprietary technology is based on gold nanoparticles, which offer significant advantages over conventional iodine-based contrast agents, including higher X-ray attenuation and longer blood circulation times. These agents can be functionalized for molecular targeting, allowing for the precise identification of high-risk atherosclerotic plaques and the characterization of solid tumors. By leveraging spectral CT capabilities, Marval's technology enables multi-color, quantitative imaging of specific biological processes. The company aims to improve the diagnosis and monitoring of life-threatening conditions in cardiovascular medicine and oncology.